Drugs / PST-611
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT07024732 | Jun 2025 → Apr 2026 | dry age related macular degeneration | Eyevensys | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT07705568 | Sep 2026 → Jun 2028 expected | age-related macular degeneration, diffuse secondary choroid atrophy | Eyevensys | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-11 | Eyevensys | Results Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026 pulsesight.com ↗
PST-611-CT1 met the primary and secondary objectives, with PST-611 demonstrating excellent safety and tolerability at both dose levels. |
| 2025-10-14 | Eyevensys | Results Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611 pulsesight.com ↗
These clinical data confirm PulseSight’s therapeutic strategy in developing PST-611, an innovative first-in-class non-viral vectorized therapy that delivers a plasmid encoding transferrin into the eye with the aim of restoring iron balance and preserve retinal structure and function in dry AMD/GA. |
| 2025-09-04 | Eyevensys | Results PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025 pulsesight.com ↗
These findings further support the development of PulseSight’s lead therapy, PST-611, a first-in-class non-viral vectorized therapy encoding transferrin to restore iron balance and preserve retinal structure and function in dry AMD/ GA. |
| 2025-06-02 | Eyevensys | Regulatory PulseSight Therapeutics receives CTA approval from ANSM for Phase I trial in France of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy pulsesight.com ↗ |
| 2025-01-14 | Eyevensys | Regulatory PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy pulsesight.com ↗
today announces it has submitted a Clinical Trial Authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a Phase I trial (PST-611-CT1) |
| 2024-11-06 | Eyevensys | Results PulseSight Therapeutics Presents New Data on PST-611 Transferrin Vectorized Therapy for Geographic Atrophy at EVER Congress 2024 pulsesight.com ↗
During his oral presentation, Dr Thierry Bordet, CSO of PulseSight showed data from a retrospective study in a large cohort of dry AMD patients confirming higher level of free iron and increased transferrin saturation in AMD patients versus control patients. |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PST-611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024732 ↗ |
| Modality | Other / unclassified | “naked plasmid DNA encoding human transferrin” NCT07705568 ↗ |
| Route | Other | “administered into the ciliary muscle” NCT07705568 ↗ |